Feb. 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its fourth quarter and full year 2024 financial results and business highlights.

In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report), with a price target of $30.00. See what stocks ...

Scotiabank analyst Greg Harrison maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a price target of $30.00. The company’s shares closed last Friday at ...

Apellis Pharmaceuticals Inc (NASDAQ:APLS) is set to release its Q4 2024 earnings on Feb 28, 2025. The consensus estimate for Q4 2024 revenue is $198.35 million, and the earnings are expected to ...

In this article, we are going to take a look at where Apellis Pharmaceuticals (NASDAQ:APLS) stands against other top insider stock buys and sells in January. Ever heard of the “January effect?” ...

Boliden AB (publ) (OTCMKTS:BDNNY – Get Free Report) has earned an average recommendation of “Reduce” from the six analysts that are presently covering the firm, MarketBeat reports.

In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against the other oversold pharma stocks to buy according to analysts. On February 20, Emily ...

Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Apellis Pharmaceuticals fourth quarter and full-year 2024 earnings conference call. [Operator Instructions] Please ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) had its target price cut by analysts at Royal Bank of Canada from $26.00 to $25.00 in a report issued on Monday,Benzinga reports.